NeoStem falls on Phase II miss

NeoStem Inc. (NASDAQ:NBS) plunged $2 (30%) to $4.78 on Tuesday after reporting that its NBS-10 stem cell therapy

Read the full 181 word article

How to gain access

Continue reading with a
two-week free trial.